Esperion Therapeutis.Inc. buy DomRuinart
Start price
25.01.21
/
50%
€22.08
Target price
€35.00
Performance (%)
30.39%
End price
08.02.21
€28.79
Summary
This prediction ended on 08.02.21 with a price of €28.79. With a performance of 30.39% the BUY prediction by DomRuinart was a big success. DomRuinart has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -34.637% | -34.637% | 59.457% | -91.677% |
| iShares Core DAX® | -2.196% | -0.532% | 12.492% | 15.176% |
| iShares Nasdaq 100 | -0.074% | 1.843% | 40.598% | 43.702% |
| iShares Nikkei 225® | -2.154% | -1.109% | 22.295% | 3.143% |
| iShares S&P 500 | -0.501% | 1.475% | 28.278% | 41.943% |
According to DomRuinart what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year